Experimental cancer drug combo tested in early trial

NCT ID NCT04157517

Terminated Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested the safety and dosing of a new drug called modakafusp alfa, given alone or with pembrolizumab, in adults with advanced solid tumors or melanoma. The study aimed to find the highest safe dose and check for side effects. It was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: modakafusp alfa (TAK-573) and pembrolizumab
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors, including melanoma.
What could go wrong: The trial was terminated early, so results are limited. It was a small, early-phase study focused on safety, not proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic malignant neoplasm metastatic melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA NEOPLASMS

Contacts and locations

Locations

Avera Cancer Institute

Sioux Falls, South Dakota, 57105, United States
Ballarat Regional Integrated Cancer Center

Ballarat, Victoria, 3350, Australia
City of Hope Comprehensive Cancer Center - Duarte

Duarte, California, 91010, United States
Cleveland Clinic Main Campus

Cleveland, Ohio, 44195, United States
Intermountain Medical Center

Murray, Utah, 84107, United States
Morristown Medical Center

Morristown, New Jersey, 07960, United States
Norris Cotton Cancer Center Lebanon

Lebanon, New Hampshire, 03756, United States
Orlando Health Cancer Institute

Orlando, Florida, 32806, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
The Angeles Clinic and Research Institute - West Los Angeles Office

Los Angeles, California, 90025, United States
The Queen Elizabeth Hospital

Woodville South, South Australia, 5011, Australia
University of California San Diego Moores Cancer Center

La Jolla, California, 92093, United States
University of Colorado Health Memorial Hospital Central

Colorado Springs, Colorado, 80909, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
West Virginia University Health Sciences Campus

Morgantown, West Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.